First-Line Third-Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.

MedComm (2020) · 2025 · PMC12592680 · PMID 41211184

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

In terms of OS (Figure 3A ), osimertinib (HR, 0.90; 95% CrI 0.83 to 0.99) and lazertinib (HR, 0.89; 95% CrI 0.79–1.00) demonstrated significant improvements compared to first‐gen TKIs, though the upper bounds approach 1, indicating borderline significance.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.